MLN8237 Inhibits Activities of p-Akt and p-p38 MAPK in HepG2 and SMMC-7721 Cells
(A and B) HepG2 (A) and SMMC-7721 (B) cells were treated with sorafenib, MLN8237, or both for 48 hr. Western blotting was then conducted to monitor the expression of p-Akt, total Akt, p-p38 MAPK, and total p38-MAPK in the cells. (C and D) HepG2 cells treated with sorafenib, MLN8237, or both for 48 hr. Immunofluorescence to determine the expression of p-Akt (C) and p-p38 MAPK (D) in HepG2 cell.